-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Reiterates Overweight on Aardvark Therapeutics, Maintains $50 Price Target

Benzinga·04/01/2025 15:05:25
Listen to the news
Cantor Fitzgerald analyst Josh Schimmer reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Overweight and maintains $50 price target.